154 related articles for article (PubMed ID: 30802002)
1. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.
de Vries Schultink AHM; Crombag MBS; van Werkhoven E; Otten HM; Bergman AM; Schellens JHM; Huitema ADR; Beijnen JH
Cancer Med; 2019 Apr; 8(4):1406-1415. PubMed ID: 30802002
[TBL] [Abstract][Full Text] [Related]
2. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
[TBL] [Abstract][Full Text] [Related]
4. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
Vermunt MAC; van der Heijden LT; Hendrikx JJMA; Schinkel AH; de Weger VA; van der Putten E; van Triest B; Bergman AM; Beijnen JH
Cancer Chemother Pharmacol; 2021 Jun; 87(6):855-869. PubMed ID: 33744986
[TBL] [Abstract][Full Text] [Related]
6. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
7. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Poon DMC; Chan K; Chan TW; Ng B; Siu S; Ng J; Johnson D; Lee KC;
Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():39-47. PubMed ID: 33860642
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
9. Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer.
Hirasawa Y; Nakashima J; Sugihara T; Takizawa I; Gondo T; Nakagami Y; Horiguchi Y; Ohno Y; Namiki K; Ohori M; Tachibana M
Clin Genitourin Cancer; 2017 Feb; 15(1):176-181. PubMed ID: 27324052
[TBL] [Abstract][Full Text] [Related]
10. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Peltekian S; Sajwani S; Wang X; Kanji S
Support Care Cancer; 2023 May; 31(5):311. PubMed ID: 37126153
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
14. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.
Crombag MBS; de Vries Schultink AHM; van Doremalen JGC; Otten HM; Bergman AM; Schellens JHM; Beijnen JH; Huitema ADR
Drugs Aging; 2019 Apr; 36(4):379-385. PubMed ID: 30734241
[TBL] [Abstract][Full Text] [Related]
15. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
Francini E; Sweeney CJ
Eur Urol; 2016 Sep; 70(3):410-2. PubMed ID: 27184379
[TBL] [Abstract][Full Text] [Related]
19. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.
Templeton AJ; Vera-Badillo FE; Wang L; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore M; Sridhar SS; Joshua AM; Pond GR; Amir E; Tannock IF
Ann Oncol; 2013 Dec; 24(12):2972-7. PubMed ID: 24126362
[TBL] [Abstract][Full Text] [Related]
20. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
Seyednasrollah F; Koestler DC; Wang T; Piccolo SR; Vega R; Greiner R; Fuchs C; Gofer E; Kumar L; Wolfinger RD; Kanigel Winner K; Bare C; Neto EC; Yu T; Shen L; Abdallah K; Norman T; Stolovitzky G; Soule HR; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Elo LL; Zhou FL; Guinney J; Costello JC;
JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
